3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
5
Phase 2
4
Phase 4
3
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 1
1
Status
Recruiting
2
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
5
Sponsor
Cancer Type
Endocrine
7
NET
5
Gastrointestinal
2
Gynecologic
1
Genitourinary
1
Conditions
Neuroendocrine Tumors
4
Carcinoid Tumor
2
Serotonin Syndrome
1
Neuroendocrine Tumors in Lung
1
Gastro-enteropancreatic neuroendocrine tumor
1
Flushing
1
Diarrhea
1
Adenoma, Islet Cell
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
6
lanreotide
5
Octreotide
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
amino-acid, glucose, and electrolyte solution
3
Capecitabine
3
surufatinib
2
pasireotide
2
fluorodopa F 18
2
Temozolomide
2
Lutetium-177
2
Lutetium
2
Introns
2
Ga(III)-DOTATOC
2
telotristat ethyl
1
pembrolizumab
1
copper dotatate CU-64
1
cabozantinib
1
X-Rays
1
Watchful Waiting
1
Sunitinib
1
Specimen Handling
1
Somatostatin
1
Serotonin
1
Salts
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Phantoms, Imaging
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
5 trials
Recent
Start date
Enrollment
Phase 3
×
lanreotide
×
NET
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT06878664
2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
166 enrolled
NCT00774930
2022-10-14
ELECT
Ipsen
Phase 3
Completed
115 enrolled
17 charts
NCT00842348
2022-10-12
NET729
Ipsen
Phase 3
Completed
89 enrolled
9 charts
NCT02683941
2022-07-06
SPINET
Ipsen
Phase 3
Terminated
77 enrolled
20 charts